Longitudinal immune programs and association with toxicity burden and antitumor response during immunotherapy.

Journal of Clinical Oncology 2026

View at publisher
Authors: Mireille Langouo Fontsa, Mario Stabile, Andrea Garavello, Soizic Garaud, Pauline Delvaux, Anouk Goudsmit, Mariana Brandão, Thierry Berghmans, Jérémy Blanc, Maxime Ilzkovitz, Louis Wolff, Anne-Pascale Meert
+7 more Anaïs Boisson, Doïna Sofronii, Loïc Baudelet, Thila Vanhulst, Francine Padonou, Ahmad Awada, Karen Willard-Gallo
DOI: 10.1200/jco.2026.44.16_suppl.2541
Cited by: 1

Abstract

2541 Background: Immune-related adverse events (irAEs) and tumor responses often co-occur during immune checkpoint inhibitor (ICI) therapy. We investigated whether blood immune programs associated with toxicity can be temporally and biologically dissociated from response programs. Methods: ICI-naïve patients with advanced solid tumors (n=37; enriched for melanoma and NSCLC) were profiled at baseline (T0), early on-treatment (T1; week 4), and later timepoints (T2–T3); patients with irAEs had an additional sample at onset (Ttox) before immunosuppression. PBMCs were analyzed by multiparameter flow cytometry and plasma cytokines by 48-plex multiplex assay (log2). We compared timepoints and delta windows (ΔT1–ΔT3), controlled multiple testing with Benjamini–Hochberg (q

Fields of Study & Subjects

Cancer Immunotherapy and Biomarkers CAR-T cell therapy research vaccines and immunoinformatics approaches

Publication details

Journal / source
Journal of Clinical Oncology
Publisher
American Society of Clinical Oncology (ASCO)
Volume
44
Issue
16_suppl
Pages
2541–2541
Publication date
27 May 2026
Language
EN